Literature DB >> 8041175

Nucleoside trapping during reperfusion prevents ventricular dysfunction, "stunning," in absence of adenosine. Possible separation between ischemic and reperfusion injury.

A S Abd-Elfattah1, M E Jessen, A S Wechsler.   

Abstract

A previous study has shown that endogenous adenosine trapping during ischemia (by blocking adenine nucleoside transport and inhibiting adenosine breakdown) prevents myocardial stunning. In this study, we tested the hypothesis that delay of administration of inhibitors until reperfusion would similarly prevent myocardial stunning in the absence of entrapped adenosine. In both studies, a selective nucleoside transport blocker, p-nitrobenzyl-thioinosine, was used in combination with a potent adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine, to entrap adenosine (preischemic treatment) or inosine (postischemic treatment) in an in vivo canine model of reversible global ischemia. Twenty-five anesthetized adult dogs were instrumented (by sonomicrometry) to monitor left ventricular performance from the relationship between stroke work and end-diastolic length as a sensitive and load-independent index of contractility. Hearts of animals supported by cardiopulmonary bypass were subjected to 30 minutes of normothermic global ischemia and 60 minutes of reperfusion. Saline solution containing the pharmacologic agents were infused into the bypass circuit before ischemia (group 1) or during reperfusion (group 2). Control group (group 3) received saline before and after ischemia. Myocardial biopsy specimens were obtained before, during, and after ischemia, and levels of adenine nucleotides, nucleosides, oxypurines, and the oxidized form of nicotinamide-adenine dinucleotide were determined. Left ventricular contractility fully recovered within 30 minutes of reperfusion in the groups treated with erythro-9-(2-hydroxy-3-nonyl)adenine and p-nitrobenzyl-thioinosine (p < 0.05 versus control group). Myocardial adenosine triphosphate was depleted by 50% in all groups at the end of ischemia. Adenosine triphosphate recovered during reperfusion only in the group that was treated with inhibitors before ischemia (group 1). At the end of ischemia, adenosine levels were low (< 10% of total nucleosides) in the control group (group 3) and in the group treated only after ischemia (group 2). A high level of adenosine (> 90% of total nucleosides) was present in group 1. We infer that selective pharmacologic blockade of nucleoside transport, only after ischemic injury, accelerated functional recovery during reperfusion, even without trapping of endogenous adenosine during ischemia and without adenosine triphosphate recovery during reperfusion. Recovery of myocardial adenosine triphosphate required preischemic treatment and adenosine entrapment during ischemia and reperfusion. Therefore, nucleoside trapping may be used to prevent reperfusion-mediated injury after reversible ischemic injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8041175

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury.

Authors:  A S Abd-Elfattah; M E Jessen; J Lekven; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

2.  Identification of nucleoside transport binding sites in the human myocardium.

Authors:  A S Abd-Elfattah; J Hoehner; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

3.  Myocardial protection in beating heart cardiac surgery: I: pre- or postconditioning with inhibition of es-ENT1 nucleoside transporter and adenosine deaminase attenuates post-MI reperfusion-mediated ventricular fibrillation and regional contractile dysfunction.

Authors:  Anwar Saad Abd-Elfattah; Hamdy Aly; Scott Hanan; Andrew S Wechsler
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-11       Impact factor: 5.209

Review 4.  Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects.

Authors:  Francisco Villarreal; Scott Zimmermann; Lala Makhsudova; Annika C Montag; Mark D Erion; David A Bullough; Bruce R Ito
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

Review 5.  Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury?

Authors:  Cui Yang; George P H Leung
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.